Scarica l'app Stockscreener
26.90
0.37%
0.10
Dopo l'orario di chiusura:
26.90
Precedente Chiudi:
$26.80
Aprire:
$26.46
Volume 24 ore:
269.86K
Relative Volume:
0.48
Capitalizzazione di mercato:
$1.81B
Reddito:
$71.30M
Utile/perdita netta:
$-354.80M
Rapporto P/E:
-4.8122
EPS:
-5.59
Flusso di cassa netto:
$-356.00M
1 W Prestazione:
-2.18%
1M Prestazione:
+7.77%
6M Prestazione:
-18.04%
1 anno Prestazione:
+53.54%
Intervallo 1D:
$25.85
$26.94
Intervallo di 1 settimana:
$25.76
$29.61
Portata 52W:
$14.02
$53.08
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results - Investing.com
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results By Investing.com - Investing.com UK
Allspring Global Investments Holdings LLC Has $182,000 Stake in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - Defense World
Wedbush Issues Pessimistic Estimate for Arvinas Earnings - Defense World
FY2024 EPS Estimates for Arvinas Cut by Leerink Partnrs - Defense World
Arvinas (NASDAQ:ARVN) Price Target Lowered to $40.00 at Oppenheimer - Defense World
Arvinas Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oppenheimer cuts Arvinas shares price target to $40 ahead of TACTIVE-U trial - Investing.com
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Assenagon Asset Management S.A. Invests $3.44 Million in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... - Yahoo Finance
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... By GuruFocus - Investing.com Canada
Arvinas Reports Progress in Q3 2024 Financials and Trials - TipRanks
Arvinas Inc (ARVN) Q3 2024 Earnings: Revenue Soars to $102.4M, B - GuruFocus.com
Arvinas (NASDAQ:ARVN) Trading 4.3% HigherTime to Buy? - MarketBeat
Arvinas earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 12.7% in October - MarketBeat
We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely - Yahoo Finance
Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential - Insider Monkey
Arvinas (ARVN) to Release Earnings on Wednesday - MarketBeat
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day - ForexTV.com
SG Americas Securities LLC Sells 76,236 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
'Arvinas stock may double if breast cancer drug beats competition'Stifel By Investing.com - Investing.com South Africa
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024 - The Manila Times
Arvinas to Report Third Quarter 2024 Financial Results and - GlobeNewswire
(ARVN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Arvinas (NASDAQ:ARVN) pops 11% this week, taking one-year gains to 81% - Simply Wall St
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause (NASDAQ:ARVN) - Seeking Alpha
Arvinas (NASDAQ:ARVN) Trading 5.9% HigherWhat's Next? - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Decrease in Short Interest - MarketBeat
ESR1-Mutated Metastatic Breast Cancer Market to Rise by 2034 | - openPR
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Millennium Management LLC Decreases Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
A new trading data show Arvinas Inc (ARVN) is showing positive returns. - SETE News
Market Recap Check: Arvinas Inc (ARVN)’s Positive Finish at 25.01, Up/Down 0.04 - The Dwinnex
ARVN underperforms with a -3.03 decrease in share price - US Post News
The Manufacturers Life Insurance Company Sells 24,376 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Trend Tracker for (ARVN) - Stock Traders Daily
Arvinas (NASDAQ:ARVN) Stock Price Up 5.8%Should You Buy? - MarketBeat
Dimensional Fund Advisors LP Buys 29,635 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Market Recap Check: Arvinas Inc (ARVN)’s Negative Finish at 24.48, Up/Down -0.89 - The Dwinnex
Arvinas Inc (ARVN)’s stock price range in the last year - US Post News
Arvinas (NASDAQ:ARVN) Shares Down 3.5% - MarketBeat
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arvinas Inc Azioni (ARVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cassidy Sean A | Chief Financial Officer |
Feb 23 '24 |
Sale |
47.05 |
1,702 |
80,079 |
181,916 |
| Peck Ronald | Chief Medical Officer |
Feb 23 '24 |
Sale |
47.05 |
1,699 |
79,938 |
67,516 |
| Taylor Ian | Chief Scientific Officer |
Feb 23 '24 |
Sale |
47.05 |
1,701 |
80,032 |
147,522 |
| Taylor Ian | Chief Scientific Officer |
Jan 04 '24 |
Option Exercise |
16.00 |
8,252 |
132,032 |
109,973 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):